Sugi Predict

Sugi Predict / Compounds / SCHEMBL17064145

SCHEMBL17064145

SCHEMBL17064145

CCOC(=O)NC(Cc1ccc(F)cc1)C(=O)OC

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NOS2 P35228 6/20 0.61
▸ NOS3 P29474 3/20 0.61
▸ NOS1 P29475 3/20 0.61
▸ CA12 O43570 1/20 0.51
▸ CA7 P43166 1/20 0.51
▸ CA9 Q16790 1/20 0.51
▸ CA14 Q9ULX7 1/20 0.51
▸ KDM4E B2RXH2 1/20 0.50
▸ ATM Q13315 2/20 0.48
▸ L3MBTL1 Q9Y468 1/20 0.48
▸ POLB P06746 1/20 0.48
▸ CTSS P25774 1/20 0.47
▸ CTSK P43235 1/20 0.47
▸ GAA P10253 1/20 0.47
▸ RAB9A P51151 1/20 0.47
▸ TSHR P16473 2/20 0.47
▸ EPHX2 P34913 1/20 0.46
▸ PPARG P37231 1/20 0.46
▸ HTT P42858 1/20 0.46
▸ ALDH1A1 P00352 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL32677087 1.00 NOS2 (0.61) NOS2NOS3NOS1CA12CA7
SCHEMBL17064146 1.00 NOS2 (0.61) NOS2NOS3NOS1CA12CA7
SCHEMBL17070606 1.00 NOS2 (0.61) NOS2NOS3NOS1CA12CA7
SCHEMBL16879113 0.90 NOS2 (0.65) NOS2NOS3NOS1CA12CA7
SCHEMBL16879114 0.90 NOS2 (0.65) NOS2NOS3NOS1CA12CA7
SCHEMBL18765748 0.89 ALDH1A1 (0.54) NOS2NOS3NOS1CA12CA7
SCHEMBL4850176 0.89 ALDH1A1 (0.54) NOS2NOS3NOS1CA12CA7
SCHEMBL32677046 0.88 ATM (0.60) NOS2NOS3NOS1ATML3MBTL1
SCHEMBL21415517 0.88 ATM (0.60) NOS2NOS3NOS1ATML3MBTL1
SCHEMBL20028165 0.88 ATM (0.60) NOS2NOS3NOS1ATML3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240368136-A1 BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2024-11-07 — — US disclosed
EP-3365334-B1 BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS OTSUKA PHARMA CO LTD (JP) 2024-07-17 — — EP disclosed
US-11939321-B2 Benzolactam compounds as protein kinase inhibitors OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2024-03-26 — — US disclosed
CN-112094259-B Iodine (III) -mediated radiofluorination 通用医疗公司 2023-09-01 — — CN disclosed
US-20230019032-A1 BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2023-01-19 — — US disclosed
CN-114948963-A Protein kinase inhibitor benzolactam compounds 大冢制药株式会社 2022-08-30 — — CN disclosed
CN-108617166-B Protein kinase inhibitor benzolactam compounds 大冢制药株式会社 2022-05-17 — — CN disclosed
US-11001575-B1 Benzolactam compounds as protein kinase inhibitors OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2021-05-11 — — US disclosed
CN-112094259-A Iodine (III) -mediated radiofluorination 通用医疗公司 2020-12-18 — — CN disclosed
CN-106458960-B Iodine (III) -mediated radiofluorination 通用医疗公司 2020-10-23 — — CN disclosed
EP-3114117-B1 IODINE(III)-MEDIATED RADIOFLUORINATION MASSACHUSETTS GEN HOSPITAL (US) 2019-10-02 — — EP disclosed
US-20190047990-A1 BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2019-02-14 — — US disclosed
EP-3365334-A1 BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS Otsuka Pharmaceutical Co., Ltd. (JP) 2018-08-29 — — EP disclosed
US-9957231-B2 Iodine(II)-mediated radiofluorination THE GENERAL HOSPITAL CORPORATION (US) 2018-05-01 — — US disclosed
WO-2018064119-A1 CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF BLADE THERAPEUTICS, INC. (US) 2018-04-05 — — WO disclosed
WO-2017068412-A1 BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2017-04-27 — — WO disclosed
CN-106458960-A Iodine (III) -mediated radiofluorination 通用医疗公司 2017-02-22 — — CN disclosed
US-20160362375-A1 Iodine(III)-Mediated Radiofluorination THE GENERAL HOSPITAL CORPORATION 2016-12-15 — — US disclosed
US-9434699-B2 Iodine(III)-mediated radiofluorination THE GENERAL HOSPITAL CORPORATION (US) 2016-09-06 — — US disclosed
US-20150252007-A1 IODINE(III)-MEDIATED RADIOFLUORINATION THE GENERAL HOSPITAL CORPORATION 2015-09-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11939321-B2 Benzolactam compounds as protein kinase inhibitors MAPK1, ALK, MAP3K1 NOS2 1823/4885NOS3 1741/4885NOS1 774/4885
US-20230019032-A1 BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS MAPK1, ALK, MAP3K1 NOS2 1823/4885NOS3 1741/4885NOS1 774/4885
US-20150252007-A1 IODINE(III)-MEDIATED RADIOFLUORINATION TPO, FLI1, SSTR3 NOS2 3123/4885NOS3 2085/4885NOS1 3955/4885
US-20240368136-A1 BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS MAPK1, ALK, MAP3K1 NOS2 1812/4885NOS3 1782/4885NOS1 771/4885
US-20190047990-A1 BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS MAPK1, ALK, MAP3K1 NOS2 1823/4885NOS3 1741/4885NOS1 774/4885
US-11001575-B1 Benzolactam compounds as protein kinase inhibitors MAPK1, ALK, MAP3K1 NOS2 1842/4885NOS3 1702/4885NOS1 787/4885
US-20160362375-A1 Iodine(III)-Mediated Radiofluorination TPO, FLI1, SSTR3 NOS2 3123/4885NOS3 2085/4885NOS1 3955/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.